Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Payers Should Brace For Next Hepatitis C Drug “Onslaught” – Express Scripts

This article was originally published in The Pink Sheet Daily

Executive Summary

Express Scripts anticipates that the launch of new treatments in 2014 will replicate some of the dynamics in the hepatitis C market in 2011.

You may also be interested in...



US Medicare Price Negotiation: Gaming FDA Approval Dates Could Delay Drug Selection

The early February date for publishing the list of products eligible for price negotiations could dictate approval strategies for drugs with potential for big sales in Medicare going forward.

Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program

Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.

Leqembi Label Recommends Alzheimer’s Patient Registry: A Nod To Medicare Evidence Demands?

FDA-approved language recommending ongoing patient monitoring through a registry is unusual but not unprecedented to address potential safety concerns.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel